CNAT vs. NRBO, AVTX, AYTU, PIRS, ORGS, TLPH, NERV, COCP, GLTO, and VBIV
Should you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include NeuroBo Pharmaceuticals (NRBO), Avalo Therapeutics (AVTX), Aytu BioPharma (AYTU), Pieris Pharmaceuticals (PIRS), Orgenesis (ORGS), Talphera (TLPH), Minerva Neurosciences (NERV), Cocrystal Pharma (COCP), Galecto (GLTO), and VBI Vaccines (VBIV). These companies are all part of the "medical" sector.
Conatus Pharmaceuticals (NASDAQ:CNAT) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Conatus Pharmaceuticals has higher revenue and earnings than NeuroBo Pharmaceuticals.
15.2% of Conatus Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 11.3% of Conatus Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of NeuroBo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Conatus Pharmaceuticals' return on equity of -48.22% beat NeuroBo Pharmaceuticals' return on equity.
Conatus Pharmaceuticals received 511 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. Likewise, 79.67% of users gave Conatus Pharmaceuticals an outperform vote while only 74.29% of users gave NeuroBo Pharmaceuticals an outperform vote.
In the previous week, NeuroBo Pharmaceuticals had 12 more articles in the media than Conatus Pharmaceuticals. MarketBeat recorded 12 mentions for NeuroBo Pharmaceuticals and 0 mentions for Conatus Pharmaceuticals. NeuroBo Pharmaceuticals' average media sentiment score of 0.43 beat Conatus Pharmaceuticals' score of 0.00 indicating that NeuroBo Pharmaceuticals is being referred to more favorably in the news media.
Conatus Pharmaceuticals has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500.
Summary
Conatus Pharmaceuticals beats NeuroBo Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
Get Conatus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Conatus Pharmaceuticals Competitors List
Related Companies and Tools
